Currently Viewing:
Newsroom
Currently Reading
Solriamfetol Launches With Schedule IV Designation, Phase 3 Study Results
August 19, 2019 – Christina Mattina
Insomnia Correlated to an Increased Risk of Heart Disease and Stroke, Study Shows
August 19, 2019 – Matthew Gavidia
Unmet Care Targets Suggest Need for Improved Diabetes Care Accessibility
August 18, 2019 – Alison Rodriguez
Inspiratory Muscle Training May Be an Option for Patients Who Decline Pulmonary Rehabilitation for COPD
August 18, 2019 – Kelly Davio
Blood Clots in MPN Related to Higher Cost, Length of Stay for Patients With MPN
August 17, 2019 – AJMC Staff
Researchers Seek to Determine Genetic Variability in Parkinson Progression
August 17, 2019 – AJMC Staff
FDA Panel Backs Use of Descovy for HIV Prevention in Men, Transgender Women
August 16, 2019 – Jaime Rosenberg
Researcher Excited About Future of Psoriasis Treatment
August 16, 2019 – Allison Inserro
This Week in Managed Care: August 16, 2019
August 16, 2019

Treating Psoriasis With Biologics May Have Cardiac Benefits

Kelly Davio
The use of biologics to treat psoriasis has increased over time, and a recent study has demonstrated that these drugs may have benefits that extend well beyond clearing patients’ skin. The study, published in Cardiovascular Research, found that biologic therapy for psoriasis was associated with a reduction in coronary artery disease.
The use of biologics to treat psoriasis has increased over time, and a recent study has demonstrated that these drugs may have benefits that extend well beyond clearing patients’ skin. The study, published in Cardiovascular Research, found that biologic therapy for psoriasis was associated with a reduction in coronary artery disease.

The study’s authors built on the knowledge that psoriasis is linked with the development of high-risk coronary plaque. They hypothesized that they could observe a reduction in inflammatory-driven phenotypes of coronary plaque, including noncalcified coronary plaque burden and lipid-rich necrotic core, in patients who were treated with inflammation-reducing biologic therapy after 1 year versus patients who were treated with drugs other than biologics.  

The study evaluated enrolled 290 participants in the NIH Psoriasis Atherosclerosis Cardiometabolic Initiative cohort, all of whom had moderate to severe psoriasis and low cardiovascular risk at baseline, from 2013 to 2018. In total, 215 of those patients completed 1 year of follow-up. Of the total number of participants, 121 initiated treatment with biologics.

The researchers found that, at 1 year, biologic therapy was associated with a 6% reduction in noncalcified plaque burden (P = .005), a reduction in necrotic core (P = .03), and no effect on fibrous burden (P = .71) versus no biologic treatment.

The decrease in noncalcified plaque burden in the patients treated with biologics was significant compared with slow plaque progression in those treated without biologics, and it was associated with biologic treatment beyond adjustment for traditional cardiovascular risk factors.

“This appears to be an anti-inflammatory effect. In the absence of improvement in other cardiovascular risk factors, and without adding new cholesterol medications, patients’ soft plaque still improved. The only change was the severity of their skin disease,” said Nehal N. Mehta, MD, head of the Lab of Inflammation and Cardiometabolic Diseases at the National Heart, Lung, and Blood Institute, and one of the study’s authors, in a statement on the team’s findings.

“Classically a heart attack is caused by 1 of 5 risk factors: diabetes, hypertension, high cholesterol, family history, or smoking,” said Mehta. “Our study presents evidence that there is a sixth factor, inflammation; and that it is critical to both the development and the progression of atherosclerosis to heart attack.”

Larger, randomized trials will be needed to better understand the association between biologic therapy for psoriasis and the positive impacts on cardiac health, concluded the authors, noting that the current study highlights the importance of systemic inflammation in coronary artery disease.   

Reference

Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721-728. doi: 10.1093/cvr/cvz009.

Related Articles

Study Examines Link Between Psoriasis, Migraine
Psoriasis Risk Rises Along With BMI, Research Finds
Survey: Why Patients With Psoriasis Turn to Complementary and Alternative Medicines
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up